arrow
E

Emmanuel C. Patin

The Institute of Cancer Research
H指数:19
被引数:2,186

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy

系统给药的第二代STING激动剂与放疗联合促进抗肿瘤免疫的预临床疗效

2026-10-150
OAAI
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

Xevinapant联合放化疗对头颈癌肿瘤免疫微环境的负面影响

2025-11-010
OA
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial

通过姑息性放疗和ATR抑制实现肿瘤控制和免疫激活,PATRIOT Part C:一项 Ib 期临床试验

2025-08-010
OAAI
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion

作者更正: Palbociclib和dsRNA传感器合作通过ER应激和调节免疫逃避来增强抗癌作用

2025-07-150
OAAI
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

PARP抑制剂talazoparib与呼肠孤病毒协同作用,在小鼠模型中体内诱导癌症杀伤和肿瘤控制

2025-07-080
OAAI
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
2025-05-250
OAAI
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy
2024-08-130
OAAI
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
2024-07-250
OAAI
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

RIPK1-specific的PROTAC降解剂通过增强免疫原性细胞死亡来实现有效的抗肿瘤活性

IMMUNITY
IF26.3
2024-07-013
OA
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
2024-01-168
OAAI